Literature DB >> 32516056

"I Want to Do It, But I Want to Make Sure That I Do It Right." Views of Patients with Parkinson's Disease Regarding Early Stem Cell Clinical Trial Participation.

Inmaculada de Melo-Martín1, Michael Holtzman2, Katrina S Hacker2.   

Abstract

Background: First-in-human clinical trials with stem cells for Parkinson's disease (PD) are on the horizon. Their epistemic success depends on ensuring the participation of a sufficient number and appropriately diverse group of patients with PD. Their ethical soundness requires that the research community ensures that subjects' decisions about whether to participate or not are consistent with participants' values, motivations, and goals. We sought to identify PD patients' knowledge, concerns, and expectations regarding early-phase stem cell research in PD.
Methods: We conducted five semi-structured focus groups with patients with PD. Group discussions were recorded, transcribed, and coded to identify participants' knowledge, concerns, and expectations regarding participation in early stem cell clinical research in PD.
Results: Four themes were generated from our data analysis: (1) participants' skepticism about the potential benefits of these trials; (2) their desire to obtain information about various aspects related to this research; (3) a recognition that accessing available knowledge was often difficult; and (4) the relevance of trusting relationships with various stakeholders. Conclusions: Participants expressed skepticism about the immediate impact of stem cell research. Nonetheless, such skepticism often reflected an appropriate consideration of the risks and potential benefits of participating in high-risk clinical trials. Despite their skepticism, participants were eager to learn more about stem cell research and clinical trials processes. They identified consistently trusted avenues of knowledge on these topics, but they often found it difficult to access relevant information or to determine its value.

Entities:  

Keywords:  Parkinson’s disease; Stem cell clinical trials; autonomy; focus groups; recruitment of subjects; trust

Year:  2020        PMID: 32516056      PMCID: PMC8212889          DOI: 10.1080/23294515.2020.1775721

Source DB:  PubMed          Journal:  AJOB Empir Bioeth        ISSN: 2329-4515


  45 in total

1.  Rising to the Challenges of Clinical Trial Improvement in Parkinson's Disease.

Authors:  Soania Mathur; Steve DeWitte; Israel Robledo; Tom Isaacs; Jon Stamford
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

2.  Therapeutic journeys: the hopeful travails of stem cell tourists.

Authors:  Alan Petersen; Kate Seear; Megan Munsie
Journal:  Sociol Health Illn       Date:  2013-11-25

3.  What motivates Parkinson's disease patients to enter clinical trials?

Authors:  Anabela Valadas; Miguel Coelho; Tiago Mestre; Leonor Correia Guedes; Maria Finisterra; Ana Noronha; Mário M Rosa; Cristina Sampaio; Joaquim J Ferreira
Journal:  Parkinsonism Relat Disord       Date:  2011-06-28       Impact factor: 4.891

4.  The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis.

Authors:  Paul S Knoepfler; Leigh G Turner
Journal:  Regen Med       Date:  2018-01-12       Impact factor: 3.806

5.  Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials.

Authors:  Rebecca D Pentz; Margaret White; R Donald Harvey; Zachary Luke Farmer; Yuan Liu; Colleen Lewis; Olga Dashevskaya; Taofeek Owonikoko; Fadlo R Khuri
Journal:  Cancer       Date:  2012-01-31       Impact factor: 6.860

6.  A comparison of the quality of informed consent for phase I oncology trials over a 30-year period.

Authors:  Laeeq Malik; James Cooper
Journal:  Cancer Chemother Pharmacol       Date:  2018-08-27       Impact factor: 3.333

7.  Participants' Understanding of Informed Consent for Biobanking: A Systematic Review.

Authors:  Elizabeth R Eisenhauer; Alan R Tait; Soo Young Rieh; Cynthia M Arslanian-Engoren
Journal:  Clin Nurs Res       Date:  2017-07-26       Impact factor: 2.075

8.  Comparable indicators of therapeutic misconception between epilepsy or Parkinson's disease patients between those with clinical trial experience and trial non-participants.

Authors:  Emmi Reijula; Arja Halkoaho; Anna-Maija Pietilä; Tuomas Selander; Kirsti Martikainen; Reetta Kälviäinen; Tapani Keränen
Journal:  Seizure       Date:  2018-06-09       Impact factor: 3.184

9.  Clinical features of Parkinson's disease patients are associated with therapeutic misconception and willingness to participate in clinical trials.

Authors:  Emmi Reijula; Anna-Maija Pietilä; Arja Halkoaho; Tuomas Selander; Kirsti Martikainen; Reetta Kälviäinen; Tapani Keränen
Journal:  Trials       Date:  2017-09-29       Impact factor: 2.279

10.  Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.

Authors:  Roger A Barker; Malin Parmar; Lorenz Studer; Jun Takahashi
Journal:  Cell Stem Cell       Date:  2017-11-02       Impact factor: 24.633

View more
  3 in total

1.  Patient and public perspectives on cell and gene therapies: a systematic review.

Authors:  Olalekan Lee Aiyegbusi; Karen Macpherson; Lauren Elston; Susan Myles; Jennifer Washington; Nisha Sungum; Mark Briggs; Philip N Newsome; Melanie J Calvert
Journal:  Nat Commun       Date:  2020-12-08       Impact factor: 14.919

Review 2.  Bringing Advanced Therapies for Parkinson's Disease to the Clinic: An Analysis of Ethical Issues.

Authors:  Kristina Hug
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

3.  Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.

Authors:  Patrick Bodilly Kane; Daniel M Benjamin; Roger A Barker; Anthony E Lang; Todd Sherer; Jonathan Kimmelman
Journal:  Mov Disord       Date:  2020-10-01       Impact factor: 10.338

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.